Can-Fite's Namodenoson Boosts Chemo Efficacy in Pancreatic Cancer — Can-Fite BioPharma Ltd.

Event summary

Can-Fite's preclinical study shows namodenoson enhances gemcitabine's anti-cancer effect in pancreatic cancer by increasing cleaved caspase-3 levels.
The findings support the design of Can-Fite’s planned Phase IIb study combining namodenoson with gemcitabine and Nab-paclitaxel.
Namodenoson suppressed key survival pathways in pancreatic cancer cells, increasing their susceptibility to chemotherapy.
Phase 2a study results for namodenoson in pancreatic cancer accepted for presentation at ESMO Congress 2026.

The big picture

Can-Fite’s findings align with the growing trend of combination therapies in oncology, where targeted drugs enhance the efficacy of standard treatments. The company’s focus on leveraging namodenoson’s mechanism of action to improve outcomes in pancreatic cancer could position it as a key player in this space, provided the Phase IIb study delivers robust results. The strategic move to combine namodenoson with existing therapies also reflects a broader industry shift toward optimizing treatment protocols for hard-to-treat cancers.

What we're watching

Clinical Trial Progress: How the Phase IIb study results will validate the combination therapy approach and impact Can-Fite’s strategic positioning.
Regulatory Pathway: Whether the positive preclinical and Phase 2a data will accelerate regulatory approvals for namodenoson in pancreatic cancer.
Market Differentiation: The pace at which Can-Fite can differentiate namodenoson in the competitive oncology market, particularly against existing chemotherapy regimens.